Literature DB >> 27181399

Exercise and Aerobic Fitness to Reduce Cancer-Related Cardiovascular Toxicity.

Umberto Campia1, Ana Barac2.   

Abstract

OPINION STATEMENT: Several cancer treatments are associated with vascular toxicity, mainly mediated by their effects on endothelial cell function. In turn, vascular dysfunction may contribute to cardiac damage and other cardiovascular side effects such as hypertension, stroke, and arterial and venous thrombosis. Aerobic exercise is associated with numerous beneficial effects on the endothelium and on cardiovascular risk factors, and may potentially modulate some of the mechanisms of vascular damage associated with antineoplastic therapies, thereby reducing their cardiovascular toxicity. To date, only a very limited number of studies have focused on the effects of supervised exercise on endothelial function in cancer patients undergoing treatment and molecular mechanisms remain to be explored. Further mechanistic, translational, and clinical research is needed to investigate the potential protective role of exercise on the vascular toxicity of cancer treatments.

Entities:  

Keywords:  Cancer treatment; Cardiovascular disease prevention; Exercise; Vascular toxicity

Year:  2016        PMID: 27181399     DOI: 10.1007/s11936-016-0465-7

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  99 in total

Review 1.  Modulation of cardiovascular toxicity in Hodgkin lymphoma: potential role and mechanisms of aerobic training.

Authors:  Anthony F Yu; Lee W Jones
Journal:  Future Cardiol       Date:  2015-08-03

2.  Exercise-induced improvement in vasodilatory function accompanies increased insulin sensitivity in obesity and type 2 diabetes mellitus.

Authors:  Elena De Filippis; Kenneth Cusi; Gloria Ocampo; Rachele Berria; Susan Buck; Agostino Consoli; Lawrence J Mandarino
Journal:  J Clin Endocrinol Metab       Date:  2006-10-03       Impact factor: 5.958

3.  The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors.

Authors:  C J Sweeney; K D Miller; S E Sissons; S Nozaki; D K Heilman; J Shen; G W Sledge
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

4.  Therapeutic properties of aerobic training after a cancer diagnosis: more than a one-trick pony?

Authors:  Lee W Jones; Mark W Dewhirst
Journal:  J Natl Cancer Inst       Date:  2014-03-13       Impact factor: 13.506

5.  Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine.

Authors:  Gianmauro Numico; Ornella Garrone; Vincenzo Dongiovanni; Nicola Silvestris; Ida Colantonio; Gianna Di Costanzo; Cristina Granetto; Marcella Occelli; Elena Fea; Abdelamid Heouaine; Milena Gasco; Marco Merlano
Journal:  Cancer       Date:  2005-03-01       Impact factor: 6.860

Review 6.  Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship.

Authors:  Amanda Nickles Fader; Lucybeth Nieves Arriba; Heidi E Frasure; Vivian E von Gruenigen
Journal:  Gynecol Oncol       Date:  2009-04-29       Impact factor: 5.482

7.  A comparative study on the anti-angiogenic effects of DNA-damaging and cytoskeletal-disrupting agents.

Authors:  Peace Mabeta; Michael S Pepper
Journal:  Angiogenesis       Date:  2009-02-12       Impact factor: 9.596

8.  Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.

Authors:  Edward H Romond; Jong-Hyeon Jeong; Priya Rastogi; Sandra M Swain; Charles E Geyer; Michael S Ewer; Vikas Rathi; Louis Fehrenbacher; Adam Brufsky; Catherine A Azar; Patrick J Flynn; John L Zapas; Jonathan Polikoff; Howard M Gross; David D Biggs; James N Atkins; Elizabeth Tan-Chiu; Ping Zheng; Greg Yothers; Eleftherios P Mamounas; Norman Wolmark
Journal:  J Clin Oncol       Date:  2012-09-17       Impact factor: 44.544

Review 9.  Neuregulin in cardiovascular development and disease.

Authors:  Oghenerukevwe Odiete; Michael F Hill; Douglas B Sawyer
Journal:  Circ Res       Date:  2012-10-26       Impact factor: 17.367

10.  Long-term physical activity trends in breast cancer survivors.

Authors:  Caitlin Mason; Catherine M Alfano; Ashley Wilder Smith; Ching-Yun Wang; Marian L Neuhouser; Catherine Duggan; Leslie Bernstein; Kathy B Baumgartner; Richard N Baumgartner; Rachel Ballard-Barbash; Anne McTiernan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04-10       Impact factor: 4.254

View more
  1 in total

Review 1.  Cardio-Oncology - A new subspecialty with collaboration at its heart.

Authors:  Arjun K Ghosh; J Malcolm Walker
Journal:  Indian Heart J       Date:  2017-05-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.